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Background: Transendocardial Stem Cell Injection (TESI) with mesenchymal stem cells improves left ventricular (LV) geometry in chronic ischemic 
cardiomyopathy, by reducing myocardial scar, LV volumes, and sphericity index. 
purpose: To address whether TESI exerts its effects at the site of injection only or also in remote areas, we hypothesized that segmental early 
enhancement defect (SEED, an indicator of myocardial scar) and segmental ejection fraction (SEF, a measure of regional contractility) improves 
more in injected than in non-injected segments. 
methods: Biplane left ventriculography and endocardial border tracings were recorded during TESI (n=30). Injections were guided by regional 
wall motion and by multidetector computerized tomography (MDCT) and targeted to scar and border zones, with 10 sites injected in each patient. 
Sites were mapped to a 17 segment model. MDCT was done before and 13 months after TESI. Four groups of myocardial segments were compared: 
segments with or without SEED, and treated or not treated with TESI. 
results: A total of 510 myocardial segments were analyzed. SEED was reduced by TESI in both injected (-43.2%±4.4 p<0.01) and non injected 
segments (-24.8%±7.9; p<0.001, between group comparison p<0.05). SEF improved in scar segments treated with TESI (19.6%±2.4 to 25.9%±2.5, 
p=0.002) but did not change in scar segments not injected (21.5%±2.0 to 23.3%±2.5, p=0.20, between group P<0.05). Non scar segments did 
not change regardless of TESI. In a subgroup of patients with global LVEF<0.20 (n=19) the SEF improvement in injected segments was even greater 
(11.9% ±1.1 to 19.8% ±2.6, p=0.001) with some improvement in the non injected segments (10.7% ±1.8 to 13.8% ±2.3, p=0.04).
conclusions: These findings illustrate important regional and patient specific insights into the responses to TESI. Although there are infarct size 
reducing effects remote from the site of injection, clearly the myocardial remodeling and functional responses are greatest at the sites of cell 
injection. Improvement was greatest when LV dysfunction was severe. Together these insights offer important guidance in the evolution of strategies 
for TESI in ischemic heart disease.
